Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: To assess the relationship between qualitative diabetic retinopathy (DR) scales with the precise numbers and surface area of DR lesions within the Early Treatment Diabetic Retinopathy Study (ETDRS) standard seven field (S7F) region on ultrawide-field (UWF) color fundus images.

Methods: In this study, we collected UWF images from adult patients with diabetes. Poor-quality images and eyes with any pathology precluding assessment of DR severity were excluded. The DR lesions were manually segmented. DR severity was graded according to the International Clinical Diabetic Retinopathy (ICDR) and AA protocol by two masked graders within the ETDRS S7F. These lesions' numbers and surface area were computed and correlated against the DR scores using the Kruskal-Wallis H test. Cohen's Kappa was performed to determine the agreement between two graders.

Results: One thousand five hundred and twenty eyes of 869 patients (294 females, 756 right eyes) with a mean age of 58.7 years were included. 47.4% were graded as no DR, 2.2% as mild non-proliferative DR (NPDR), 24.0% as moderate NPDR, 6.3% as severe NPDR, and 20.1% as proliferative DR (PDR). The area and number of DR lesions generally increased as the ICDR level increased up to severe NPDR, but decreased from severe NPDR to PDR. There was perfect intergrader agreement on the DR severity.

Conclusion: A quantitative approach reveals that DR lesions' number and area generally correlate with ICDR-based categorical DR severity levels with an increasing trend in the number and area of DR lesions from mild to severe NPDR and a decrease from severe NPDR to PDR.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587246PMC
http://dx.doi.org/10.1007/s00417-023-06145-7DOI Listing

Publication Analysis

Top Keywords

diabetic retinopathy
20
severe npdr
20
surface area
12
numbers surface
8
area lesions
8
npdr pdr
8
number area
8
npdr
7
area
6
retinopathy
5

Similar Publications

Diabetic retinopathy (DR) remains a leading cause of preventable blindness worldwide, with the affected population projected to reach 270 million by 2045. Our study analyzed 2 434 interventional trials registered between 2007 and 2024 in the Informa Pharma Intelligence database and found that anti-VEGF agents dominate the therapeutic landscape-bevacizumab represents 24.0 % of studies, ranibizumab 15.

View Article and Find Full Text PDF

Purpose: To evaluate macular vessel density using clinical parameters in patients with type 2 diabetes mellitus (DM) without retinopathy.

Patients And Methods: This cross-sectional study enrolled 32 participants (63 eyes) aged 40-60 years who met the inclusion criteria. Group 1 included 32 eyes of type 2 DM, whereas the rest had no DM.

View Article and Find Full Text PDF

Organoids: their emerging essential role in pathological mechanisms and drug discovery of diabetes and its complications.

Front Pharmacol

August 2025

State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Beijing, China.

Diabetes mellitus is a metabolic disease with a high global prevalence, which affects blood vessels throughout the entire body. As the disease progresses, it often leads to complications, including diabetic retinopathy and nephropathy. Currently, in addition to traditional cellular and animal models, more and more organoid models have been used in the study of diabetes and have broad application prospects in the field of pharmacological research.

View Article and Find Full Text PDF

Background: Artificial intelligence (AI) algorithms offer an effective solution to alleviate the burden of diabetic retinopathy (DR) screening in public health settings. However, there are challenges in translating diagnostic performance and its application when deployed in real-world conditions.

Objective: This study aimed to assess the technical feasibility of integration and diagnostic performance of validated DR screening (DRS) AI algorithms in real-world outpatient public health settings.

View Article and Find Full Text PDF

Dapagliflozin improves diabetic retinopathy in mice by inhibiting LAMA1 and regulating the PI3K/AKT signaling pathway.

Biochem Biophys Res Commun

September 2025

Department of Ophthalmology, Hebei Medical University, NO. 361 Zhongshan East Road, Changan District, Shijiazhuang City, Hebei Province, China; Department of Ophthalmology, Hebei General Hospital, NO. 348 Heping West Road, Xinhua District, Shijiazhuang City, Hebei Province, China. Electronic address

Diabetic retinopathy (DR) is among the most prevalent complications linked to advanced diabetes. Capillary Basement membrane (CBM) thickening is an early clinical manifestation in DR, and Laminin α 1 (LAMA1) is one of the main extracellular matrix components involved in CBM formation. Dapagliflozin (DAPA) has demonstrated efficacy in ameliorating DR.

View Article and Find Full Text PDF